Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01043549

Acronym

rTMSPPCGT

Enrollment

Registered

2010-01-06

Start date

2010-02-28

Completion date

2012-09-30

Last updated

2016-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gilles de la Tourette Syndrome, Tics

Keywords

Gilles de la Tourette syndrome, Tics, Transcranial magnetic stimulation

Brief summary

Repetitive transcranial stimulation (rTMS) of the posterior parietal cortex will be applied daily over five days in adult Gilles de la Tourette patients. This approach aims at reducing premonitory sensations believed to induce tics. Patients will be randomized to an active or placebo (sham) group in a crossover design.

Interventions

DEVICErTMS

Repetitive transcranial stimulation of the posterior parietal cortex

DEVICESham rTMS

Repetitive transcranial stimulation of the posterior parietal cortex

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Gilles de la Tourette syndrome as defined by DSM IV-R * Yale Global Tics Severity Scale (YGTSS) score between 30 et 60 * Premonitory sensations ( urge to move ) * Affiliated to the French social security regime * Ability to give informed consent

Exclusion criteria

* rTMS : epilepsy, craniotomy scar, pacemaker or neural stimulator, metal implants or foreign bodies, claustrophobia, pregnancy * Cognitive impairment (MMS ≤ 24/30) * Axis I disorders according to DSM IV-R : psychosis or history of psychosis, bipolar illness, major depressive disorder, addictions (except to nicotine) * Impulse control disorders * Other chronic debilitating illnesses * Unability to give informed consent * Participation in another clinical trial

Design outcomes

Primary

Measure	Time frame
Yale global tic severity scale (YTGSS)	3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026